Key takeaway: The investor presentation for Gujarat Kidney And Super Speciality Limited (GKSL) outlines the company's strategic and financial highlights for FY26 and Q2 FY27. The company is contemplating an initial public offering (IPO) and has submitted a draft red herring prospectus to BSE and NSE. Financial performance shows significant growth, with revenue from operations increasing by 104% YoY to ₹8,201 lakhs in FY26 and further rising by 11% QoQ to ₹3,809 lakhs in Q2 FY27. EBITDA grew by 63% YoY to ₹1,681 lakhs in FY26 and expanded to ₹1,022 lakhs in Q2 FY27 with a margin of 26.8%. PAT increased by 77% YoY to ₹1,681 lakhs in FY26 and rose by 24% QoQ to ₹660 lakhs in Q2 FY27. The company has continued inorganic expansion, with ₹1,669 lakhs deployed in acquisitions during H1 FY27, leading to an increase in goodwill. Operating leverage has improved margins, with EBITDA margin rising to 26.8% from 24.4% QoQ. Clinical volumes have scaled up, with H1 FY27 showing 11,040 IPD admissions and 78,643 OPD visits, reaching 83% and 82% of FY26 full-year volumes. The balance sheet remains strong, with net worth at ₹26,364 lakhs and net cash of ₹1,488 lakhs. The company's strategic focus includes expanding its hospital network through acquisitions, enhancing clinical capabilities, and leveraging its asset-light model. The presentation also highlights the company's leadership, operational strengths, and future growth plans, including entry into Dubai's healthcare market through a majority stake in an established polyclinic.